Literature DB >> 12576292

Adenosine receptors in the nervous system: pathophysiological implications.

J A Ribeiro1, A M Sebastião, A de Mendonça.   

Abstract

Adenosine is a ubiquitous homeostatic substance released from most cells, including neurones and glia. Once in the extracellular space, adenosine modifies cell functioning by operating G-protein-coupled receptors (GPCR; A(1), A(2A), A(2B), A(3)) that can inhibit (A(1)) or enhance (A(2)) neuronal communication. Interactions between adenosine receptors and other G-protein-coupled receptors, ionotropic receptors and receptors for neurotrophins also occur, and this might contribute to a fine-tuning of neuronal function. Manipulations of adenosine receptors influence sleep and arousal, cognition and memory, neuronal damage and degeneration, as well as neuronal maturation. These actions might have therapeutic implications for neurodegenerative diseases such as Parkinson's disease, Alzheimer's disease, as well as for other neurological situations such as epilepsy, idiopathic pain or even drug addition. Peripheral side effects associated with adenosine receptor agonists limit their usefulness in therapeutics; in contrast, adenosine receptor antagonists appear to have less side effects as it is the case of the well-known non-selective antagonists theophylline (present in tea) or caffeine (abundant in coffee and tea), and their emerging beneficial actions in Parkinson's disease and Alzheimer's disease are encouraging. A(1) receptor antagonism may also be useful to enhance cognition and facilitate arousal, as well as in the periphery when deficits of neurotransmitter release occur (e.g. myasthenic syndromes). Enhancement of extracellular adenosine levels through drugs that influence its metabolism might prove useful approaches in situations such as neuropathic pain, where enhanced activation of inhibitory adenosine A(1) receptors is beneficial. One might then consider adenosine as a fine-tuning modulator of neuronal activity, which via subtle effects causes harmonic actions on neuronal activity. Whenever this homeostasis is disrupted, pathology may be installed and selective receptor antagonism or agonism required. Copyright 2003 Elseiver Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12576292     DOI: 10.1016/s0301-0082(02)00155-7

Source DB:  PubMed          Journal:  Prog Neurobiol        ISSN: 0301-0082            Impact factor:   11.685


  113 in total

1.  Regulation of hippocampal cannabinoid CB1 receptor actions by adenosine A1 receptors and chronic caffeine administration: implications for the effects of Δ9-tetrahydrocannabinol on spatial memory.

Authors:  Vasco C Sousa; Natália Assaife-Lopes; Joaquim A Ribeiro; Judith A Pratt; Ros R Brett; Ana M Sebastião
Journal:  Neuropsychopharmacology       Date:  2010-10-06       Impact factor: 7.853

2.  Effects of A₂A adenosine receptor blockade or stimulation on alcohol intake in alcohol-preferring rats.

Authors:  Maria Vittoria Micioni Di Bonaventura; Carlo Cifani; Catia Lambertucci; Rosaria Volpini; Gloria Cristalli; Rino Froldi; Maurizio Massi
Journal:  Psychopharmacology (Berl)       Date:  2011-08-11       Impact factor: 4.530

3.  Inhibition of Transient Receptor Potential Channel Mucolipin-1 (TRPML1) by Lysosomal Adenosine Involved in Severe Combined Immunodeficiency Diseases.

Authors:  Xi Zoë Zhong; Yuanjie Zou; Xue Sun; Gaofeng Dong; Qi Cao; Aditya Pandey; Jan K Rainey; Xiaojuan Zhu; Xian-Ping Dong
Journal:  J Biol Chem       Date:  2017-01-13       Impact factor: 5.157

4.  Purines and the Anti-Epileptic Actions of Ketogenic Diets.

Authors:  Susan A Masino; Masahito Kawamura; David N Ruskin; Jeremy Gawryluk; Xuesong Chen; Jonathan D Geiger
Journal:  Open Neurosci J       Date:  2010-01-01

5.  Modulation of visual inputs to accessory optic system by theophylline during hypoxia.

Authors:  Michael Ariel
Journal:  Exp Brain Res       Date:  2006-01-24       Impact factor: 1.972

6.  Test-retest stability of cerebral A1 adenosine receptor quantification using [18F]CPFPX and PET.

Authors:  David Elmenhorst; Philipp T Meyer; Andreas Matusch; Oliver H Winz; Karl Zilles; Andreas Bauer
Journal:  Eur J Nucl Med Mol Imaging       Date:  2007-01-23       Impact factor: 9.236

Review 7.  Adenosine augmentation therapies (AATs) for epilepsy: prospect of cell and gene therapies.

Authors:  Detlev Boison
Journal:  Epilepsy Res       Date:  2009-05-09       Impact factor: 3.045

8.  Activation of NTS A2a adenosine receptors differentially resets baroreflex control of renal vs. adrenal sympathetic nerve activity.

Authors:  Tomoko K Ichinose; Donal S O'Leary; Tadeusz J Scislo
Journal:  Am J Physiol Heart Circ Physiol       Date:  2009-02-06       Impact factor: 4.733

9.  Nucleus tractus solitarii A(2a) adenosine receptors inhibit cardiopulmonary chemoreflex control of sympathetic outputs.

Authors:  Zeljka Minic; Donal S O'Leary; Tadeusz J Scislo
Journal:  Auton Neurosci       Date:  2013-10-25       Impact factor: 3.145

10.  Altered mitochondrial ATP synthase expression in the rat dorsal root ganglion after sciatic nerve injury and analgesic effects of intrathecal ATP.

Authors:  Kuan-Hung Chen; Chung-Ren Lin; Jiin-Tsuey Cheng; Jen-Kun Cheng; Wen-Tzu Liao; Chien-Hui Yang
Journal:  Cell Mol Neurobiol       Date:  2013-09-19       Impact factor: 5.046

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.